Zevra Drug Patent Portfolio
Zevra owns 2 orange book drugs protected by 8 US patents Given below is the list of Zevra's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8461137 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | 22 Feb, 2031 | Active |
| US8748413 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | 01 Jul, 2030 | Active |
| US8828978 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | 01 Jul, 2030 | Active |
| US9132125 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | 01 Jul, 2030 | Active |
| US9549923 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof | 01 Jul, 2030 | Active |
| US11045460 | Use of Hsp70 as a regulator of enzymatic activity | 19 Aug, 2029 | Active |
| US9289472 | Use of HSP70 as a regulator of enzymatic activity | 11 Aug, 2029 | Active |
| US9884058 | Use of Hsp70 as a regulator of enzymatic activity | 26 Jun, 2029 | Active |
Latest Legal Activities on Zevra's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Zevra.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US11045460 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US11045460 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US8748413 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US9289472 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US9884058 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US8461137 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US9549923 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US9132125 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 12 Aug, 2025 | US8828978 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Aug, 2025 | US9884058 |
| Second letter to regulating agency to determine regulatory review period | 13 Jun, 2025 | US11045460 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Mar, 2025 | US11045460 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 11 Dec, 2024 | US8461137 |
| Initial letter Re: PTE Application to regulating agency | 02 Dec, 2024 | US11045460 |
| Patent Term Extension Application under 35 USC 156 Filed | 15 Nov, 2024 | US11045460 |
Zevra's Family Patents
Zevra drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 39.5% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Zevra Drug List
Given below is the complete list of Zevra's drugs and the patents protecting them.
1. Apadaz
Apadaz is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8461137 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
22 Feb, 2031
(4 years from now)
| Active |
| US8748413 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
01 Jul, 2030
(4 years from now)
| Active |
| US8828978 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
01 Jul, 2030
(4 years from now)
| Active |
| US9132125 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
01 Jul, 2030
(4 years from now)
| Active |
| US9549923 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof |
01 Jul, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apadaz's drug page
2. Miplyffa
Miplyffa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11045460 | Use of Hsp70 as a regulator of enzymatic activity |
19 Aug, 2029
(3 years from now)
| Active |
| US9289472 | Use of HSP70 as a regulator of enzymatic activity |
11 Aug, 2029
(3 years from now)
| Active |
| US9884058 | Use of Hsp70 as a regulator of enzymatic activity |
26 Jun, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miplyffa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List